Previous 10 | Next 10 |
COMPASS Pathways plc (Nasdaq: CMPS) announced further results from its groundbreaking phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD). Compass said that additional analyses of primary and secondary endpoints validated topli...
Additional analyses of mid-stage data from COMPASS Pathways' (NASDAQ:CMPS) psilocybin therapy for depression showed it also led to improvements in anxiety, quality of life, positive and negative affect, functioning, and cognition. Results on COMP360 showed that the greatest improvements were ...
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse events demonstrate COMP360 psilocybin therapy was generally well-tolerated London, UK...
LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three investor conferences as follows: ...
Compass Pathways (NASDAQ: CMPS) has released data for a phase 2b study of its COMP360 psilocybin treatment for depression. In this Motley Fool Live video recorded on November 15 , Motley Fool contributors Keith Speights and Brian Orelli point out that the therapy helped redu...
Compass Pathways is the category leader in developing psilocybin to treat depression and other CNS disorders. The company's lead asset, COMP360, has very promising efficacy data, but more data is needed to get clarification on safety concerns. As a result, we recommend monitoring ...
COMPASS Pathways (NASDAQ:CMPS) has been granted a patent for treating treatment-resistant depression with crystalline psilocybin. The substance is used in COMP360, the company's lead asset. The candidate is currently in phase 2 for treatment-resistant depression. The patent is the fifth ...
London, UK - 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent an...
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion therapy for the treatment of mental health disorders and t...
Do you ever get the feeling the stock market isn't reading the same news that you are? Compass Pathways (NASDAQ: CMPS) shareholders know that feeling. The clinical-stage drugmaker recently told investors its psilocybin-based treatment hit high marks in a closely watched depression s...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...